AB0294 PREDICTORS OF CHLOROQUINE AND DERIVATES TREATMENT INVOLVING OCULAR TOXICITY: RESULTS FROM A COHORT

Background: Chloroquine (CQ) and hydroxychloroquine (HCQ) have been employed in a huge range of indications, from autoimmune diseases (such as rheumatoid arthritis [RA], cutaneous lupus or systemic erythematosus [SLE]) to infectious ones (as malaria helminthiasis). 1 A newer purpose came upon the new coronavirus disease 2019 (COVID-19), where they seem be effective modulating immune response. Controversial results published clinical observational data concerning its effectiveness. 2 Ocular toxicity described serious adverse event these antimalarial drugs screening protocols displayed for prevention. 3 Objectives: To evaluate CQ/HCQ ocular identify potential predictors appearance. Also asses compliance. Methods: Demographic, diagnostic treatment were collected patients under CQ HCQ Clinical University Hospital Santiago de Compostela (Spain) during first wave COVID-19 pandemic (January April 2020). Univariable logistic regression was performed maculopathy. Variables with p<0.20 selected multivariable testing. Stata 15.1 used perform statistical analysis. Results: 503 taking identified. 495 women. Most frequent diagnosis SLE (48.28%), (22.85%) (RA, 12.54%). Mean age at 44.99 years (SD 17,88). 93.33% HCQ. beginning 48.10 17.79) mean time between onset 2.03 5.50). maximum dosage per patient 3.83 mg/kg 1,59; 252.57 mg day, SD 89.98) 3.24 1,91; 219.49 103.90). 6.39 5.63). 20 developed maculopathy appearance 2.67 3.10). Only 25 did not complete ophthalmologic exams screening. After univariable analysis, higher identified (p<0.20). both suffering (OR 1.06 [CI95% 1.03-1.10] p=0.000 OR 1.09 1.02-1.16] p=0.008, respectively). Conclusion: remains one most harmful disabling events treatment. Higher appear risk factors Screening are well-assumed by seemed helpful preventing early identifying events. usage should individualized, specially older patients, involving implemented follow-up this population. References: [1]T Dörner. Hydroxychloroquine SLE: old drug, perspectives. Nat Rev Rheumatol 6, 10-11 (2010). [2]S Chowdhury, J Rathod, Gernsheimer. rapid systematic review trials utilizing chloroquine COVID-19. Acad Emerg Med. 2020;27(6):493-504. [3]J C S Yam, K H Kwok. hydroxychloroquine. Hong Kong Med J. 2006;12(4):294-304. Disclosure Interests: None declared